Drs. Bruce Rosengard and Sanuj Ravindran Join The Medicines Company New Business Ventures Team
PARSIPPANY, NJ--(Marketwire - July 19, 2012) - The Medicines Company (NASDAQ: MDCO) today announced the appointments of Bruce R. Rosengard and Sanuj K. Ravindran as Vice Presidents, New Business Ventures. Dr. Rosengard is a cardiothoracic surgeon who most recently led the cardiac transplantation team at the Massachusetts General Hospital. Dr. Ravindran is an internist by training who has been focused on healthcare and life science investing since 2003, with particular experience in the Asia Pacific region.
Glenn Sblendorio, President and Chief Financial Officer at The Medicines Company, stated, "To be a leading provider of solutions for acute | intensive care hospitals worldwide, one of our goals is to lead in portfolio depth and breadth. Adding Bruce and Sanuj reflects our intent to focus on new business ventures related to approved products and late stage development assets that offer improved solutions for our customers and leverage our current business infrastructure."
Dr. Rosengard stated, "Joining The Medicines Company provides a completely new set of opportunities and challenges for me in an arena that is very familiar. The Company is focused on affecting patient care in the areas of cardiovascular disease and critical care medicine, where I have dedicated my career. The challenge of this new opportunity is to innovate for the broad benefit of nearly 3,000 hospitals around the world and, more importantly, the millions of patients that they care for."
Dr. Ravindran added, "I have observed the global reach of The Medicines Company and see a major opportunity. I believe we can leverage our emerging infrastructure in Asia Pacific and our established operations in Europe and the Americas toward significant growth."
About Bruce R. Rosengard, MD
Dr. Bruce Rosengard is a cardiothoracic surgeon who joins The Medicines Company from the Massachusetts General Hospital and Harvard Medical School, where he was the Surgical Director of Cardiac Transplantation and ran an NIH-funded laboratory in transplantation immunology. Prior to this, he was the inaugural British Heart Foundation Professor and Chairman at Papworth Hospital and the University of Cambridge, where he pioneered "beating heart" transplantation. Dr. Rosengard started his career at The University of Pennsylvania, where he performed the first combined heart-lung transplant at that institution, described a novel cellular mechanism responsible for the triggering of transplant rejection, and patented a stem cell-based therapy to treat congestive heart failure. He graduated summa cum laude from Tufts University and obtained his MD degree from Johns Hopkins, where he completed his postgraduate training in general surgery, cardiothoracic surgery, and surgical critical care. He also completed a two-year postgraduate fellowship in transplantation immunology at the National Cancer Institute. Dr. Rosengard has more than 80 peer-reviewed publications, has given more than 40 invited talks at national or international meetings, and has served on the Boards of several professional societies.
About Sanuj K. Ravindran, MD
Dr. Sanuj Ravindran is a physician trained in Internal Medicine and has been focused on healthcare and life science investing since 2003. He was most recently a Managing Director at Asian Healthcare Fund, a New Delhi based private equity firm focused on growth-stage healthcare and life sciences companies in India, Middle East/North Africa and Southeast Asia. He was a past Principal at Radius Ventures where he invested in and assumed Board roles with several life science companies, including Targanta Therapeutics. Prior to Radius, he was Director in the Venture Capital Group and Head of the India Group at Burrill & Company. He graduated with honors from Northwestern University and also holds an MBA from Northwestern's Kellogg School of Management, where he was a Rothschild Scholar. His MD is from Jefferson Medical College of Thomas Jefferson University and he completed his residency in Internal Medicine at Thomas Jefferson University Hospital. Currently, Dr. Ravindran is a member of the Society of Kauffman Fellows, serves on the Editorial Board of Biotechnology-Healthcare and is a Senior Scholar at the Jefferson School of Population Health.
About The Medicines Company
The Medicines Company (NASDAQ: MDCO) provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients. The Medicines Company's website is www.themedicinescompany.com.
Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "intends," "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include the extent of the commercial success of Angiomax, the Company's ability to develop its global operations and penetrate foreign markets, whether the Company's products will advance in the clinical trials process on a timely basis or at all, whether the Company will make regulatory submissions for product candidates on a timely basis, whether its regulatory submissions will receive approvals from regulatory agencies on a timely basis or at all, whether physicians, patients and other key decision makers will accept clinical trial results, risks associated with the establishment of international operations, whether the Company is able to obtain or maintain patent protection for the intellectual property relating to the Company's products; and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Quarterly Report on Form 10-Q filed on May 10, 2012, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.